Eterna Therapeutics IncNASDAQ:ERNA
- LAST PRICE3.4000
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots3.4100/ 1
- Ask / Lots3.5000/ 34
- Open / Previous Close3.4999 / 3.4000
- Day Range
- 52 Week Range
- Volume1,137
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ERNA |
|---|---|---|
| 10:12 ET | 100 | 3.4999 |
| 12:16 ET | 150 | 3.414 |
| 02:04 ET | 100 | 3.4 |
| 03:34 ET | 100 | 3.4 |
Mar 28, 2023
Jeff Karp, Ph.D., Joins Eterna's Scientific Advisory Board, from 8:30AM ET on Tuesday Mar 28, 2023 by GlobeNewswire
8:30AM ET on Tuesday Mar 28, 2023 by GlobeNewswire
Mar 21, 2023
Sector Update: Health Care Stocks Lifted with Broader Markets, from 4:09PM ET on Tuesday Mar 21, 2023 by MT Newswires
4:09PM ET on Tuesday Mar 21, 2023 by MT NewswiresSector Update: Healthcare, from 3:46PM ET on Tuesday Mar 21, 2023 by MT Newswires
3:46PM ET on Tuesday Mar 21, 2023 by MT NewswiresBRIEF-Eterna Therapeutics Files Prospectus Relates To Offering, Resale From Time To Time By Selling Stockholder Of Up To 685,714 Shares Of Common Stock, from 8:42AM ET on Tuesday Mar 21, 2023 by Thomson Reuters
8:42AM ET on Tuesday Mar 21, 2023 by Thomson Reuters
Mar 20, 2023
Eterna Therapeutics Lowers Q4 Net Loss by Almost 60%; Shares Up After-Hours, from 4:42PM ET on Monday Mar 20, 2023 by MT Newswires
4:42PM ET on Monday Mar 20, 2023 by MT Newswires
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Eterna Therapeutics Inc | 17.4M | -0.4x | --- |
Microbot Medical Inc | 17.4M | -1.1x | --- |
Acer Therapeutics Inc | 17.6M | -0.5x | --- |
Chemomab Therapeutics Ltd | 17.1M | 0.0x | --- |
GeoVax Labs Inc | 17.2M | -0.7x | --- |
Frequency Therapeutics Inc | 16.9M | -0.2x | --- |
Company Information
Eterna Therapeutics Inc. is a preclinical-stage biopharmaceutical company. The Company is focused on developing advanced therapies using messenger ribonucleic acid (RNA) (mRNA) cell engineering technology. The Company has a portfolio of over 100 patents covering mRNA cell engineering technologies, including technologies for mRNA cell reprogramming, mRNA gene editing, the NoveSlice and UltraSlice gene-editing proteins, and the ToRNAdo mRNA delivery system, which the Company collectively refers to as its mRNA technology platform. Its mRNA gene-editing technology is designed to delete, insert, and repair deoxyribonucleic acid (DNA) sequences in living cells, which may be useful for correcting disease-causing mutations, making cells resistant to infection and degenerative disease, modulating the expression of immunoregulatory proteins to enable the generation of durable allogeneic cell therapies, and engineering immune cells to fight cancer.
Contact Information
- Headquarters
- 1035 Cambridge Street, Suite 18ACAMBRIDGE, MA, United States 02141
- Phone
- 212-582-1199
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Charles Cherington
- President, Chief Executive Officer, Director
- Matthew Angel
- Chief Financial Officer
- Andrew Jackson
- Chief Administrative Officer
- Jay Sial
- Vice President - Finance
- Sandra Gurrola
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $17.4M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 5.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 4.37 |
EPS | $-8.38 |
Book Value | $2.36 |
P/E Ratio | -0.4x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
